KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Inventory: 2009-2024

Historic Inventory for Teva Pharmaceutical Industries (TEVA) over the last 16 years, with Dec 2024 value amounting to $3.0 billion.

  • Teva Pharmaceutical Industries' Inventory fell 16.06% to $3.3 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $3.3 billion, marking a year-over-year decrease of 16.06%. This contributed to the annual value of $3.0 billion for FY2024, which is 25.22% down from last year.
  • Teva Pharmaceutical Industries' Inventory amounted to $3.0 billion in FY2024, which was down 25.22% from $4.0 billion recorded in FY2023.
  • Over the past 5 years, Teva Pharmaceutical Industries' Inventory peaked at $4.4 billion during FY2020, and registered a low of $3.0 billion during FY2024.
  • Over the past 3 years, Teva Pharmaceutical Industries' median Inventory value was $3.8 billion (recorded in 2022), while the average stood at $3.6 billion.
  • Its Inventory has fluctuated over the past 5 years, first rose by 4.90% in 2023, then dropped by 25.22% in 2024.
  • Over the past 5 years, Teva Pharmaceutical Industries' Inventory (Yearly) stood at $4.4 billion in 2020, then fell by 13.29% to $3.8 billion in 2021, then increased by 0.39% to $3.8 billion in 2022, then rose by 4.90% to $4.0 billion in 2023, then dropped by 25.22% to $3.0 billion in 2024.